How to calculate GRACE in-hospital and 6-month mortality risk, what each risk category means for management, invasive vs conservative strategy timing, antiplatelet therapy, and ACS in India.
A patient arrives in your emergency department with chest pain. The ECG shows no ST elevation. Troponin is being sent. Is this person at low risk — muscle pain or oesophageal spasm — or are they in the middle of a heart attack that will kill them tonight? And if it is a heart attack, do they need the cath lab in the next 2 hours, 24 hours, or can they be stabilised medically?
The GRACE score (Global Registry of Acute Coronary Events) is the tool that answers these questions. Derived from over 100,000 patients across 14 countries, it uses eight clinical variables to precisely predict in-hospital and 6-month mortality in patients with acute coronary syndrome (ACS) — and directly drives the most consequential treatment decision in cardiology: when to take the patient to the catheterisation laboratory.
Acute coronary syndrome is an umbrella term for three related conditions caused by reduced blood flow to the heart, usually from coronary artery plaque rupture and thrombus formation:
Together, NSTEMI and UA are referred to as NSTE-ACS — the primary domain of the GRACE score.
| Variable | What It Captures | Clinical Note |
|---|---|---|
| Age | Each decade significantly increases mortality | Strongest single predictor — age > 75 carries very high risk |
| Heart Rate | Tachycardia reflects haemodynamic compromise | HR > 100 bpm at presentation adds significant points |
| Systolic BP | Hypotension = cardiogenic shock risk | SBP < 100 mmHg adds very high points; low BP = high risk |
| Creatinine | Renal impairment worsens ACS outcomes dramatically | Even mild elevation (1.2–1.5 mg/dL) adds significant risk |
| Killip Class | Degree of heart failure at presentation | Class I = no CHF; Class II = rales; Class III = pulmonary oedema; Class IV = cardiogenic shock |
| Cardiac Arrest at Admission | Resuscitated cardiac arrest = very high risk | Binary yes/no — adds large number of points if yes |
| ST-Segment Deviation | ECG changes reflecting ischaemia severity | ST depression or transient elevation in NSTE-ACS adds points |
| Elevated Cardiac Biomarkers | Positive troponin = myocardial necrosis confirmed | Positive troponin significantly increases GRACE score |
❤️ Use the RxMedCalc GRACE Score Calculator — calculates in-hospital and 6-month mortality with automatic risk stratification and ESC 2023 invasive strategy timing guidance.
The single most important application of the GRACE score in NSTE-ACS is determining when to perform coronary angiography (with a view to PCI or CABG):
| Condition / Risk | Strategy | Timing |
|---|---|---|
| Very high risk — any of: haemodynamic instability, cardiogenic shock, refractory chest pain, acute heart failure, life-threatening arrhythmias, mechanical complications | Immediate invasive | Within 2 hours — regardless of GRACE score |
| High risk — GRACE > 140, dynamic ECG changes, elevated troponin, or GRACE < 140 but HEART score high | Early invasive | Within 24 hours |
| Intermediate risk — GRACE 109–140, diabetes, renal impairment, reduced EF < 40%, prior PCI/CABG, recurrent symptoms | Invasive within 72 hours | 24–72 hours |
| Low risk — GRACE ≤ 108, no high-risk features, non-obstructive CAD or normal angiogram possible | Conservative / selective invasive | Non-invasive testing first (stress echo, CT coronary angiography) before angiography decision |
⚠️ Very high risk features override GRACE score. A patient with cardiogenic shock or refractory ischaemia goes to the cath lab immediately — regardless of what the GRACE score calculates. GRACE guides timing; it does not replace clinical urgency assessment.
The Killip class is one of the variables in the GRACE score and also stands alone as an important bedside assessment of cardiac failure severity in ACS:
| Killip Class | Clinical Features | In-Hospital Mortality (Historical) |
|---|---|---|
| Class I | No evidence of heart failure — no rales, no S3 | ~6% |
| Class II | Mild-moderate heart failure — basal rales < 50% of lung fields, S3 gallop, elevated JVP | ~17% |
| Class III | Severe heart failure — pulmonary oedema, rales > 50% of lung fields | ~38% |
| Class IV | Cardiogenic shock — hypotension + end-organ hypoperfusion (cold extremities, oliguria, altered consciousness) | > 60% |
All NSTE-ACS patients without contraindication should receive aspirin + a P2Y12 inhibitor as soon as the diagnosis is established:
All NSTE-ACS patients should also receive anticoagulation in addition to antiplatelet therapy:
The introduction of high-sensitivity troponin (hs-Tn) assays has transformed NSTE-ACS diagnosis. The ESC 0/1-hour or 0/2-hour algorithm using hs-Tn allows rapid rule-in or rule-out of NSTEMI:
In India, hs-Tn assays are increasingly available in tertiary and secondary care centres. Where conventional troponin is still used, 6-hourly serial testing remains the standard.
ACS in India has several important epidemiological and clinical features that differ from Western populations:
This article is for educational purposes based on ESC 2023 and CSI guidelines. ACS management decisions — including timing of angiography and antiplatelet/anticoagulant choice — must be made by a qualified cardiologist with full clinical assessment.
Built by an MBBS, AFIH Certified Physician in Punjab, India | RxMedCalc.com